Abstract
Migraine is the most common cause of vascular headache and a highly prevalent illness. In the last 20 years, the discovery of new agents has increased clinical research on migraine. In most of clinical trials that have been conducted, the efficacy was established using a placebo as a control treatment. The objective of the study reported here was to analyse the response rate in patients who received a placebo as well as to determine how a number of the methodological factors may affect the effect of the placebo in clinical trials of acute migraine. Computer-based information searches were conducted on the Medline database. Data analysis included the outcomes ‘pain relief’, ‘pain-free’, ‘associated symptoms’, ‘recurrence’, ‘patients’ opinion’ about pain relief and ‘adverse events’. Administration route, study design and country in which the study was carried out were the methodological factors that were analyzed. Meta-analysis was computed using Mantel-Haenszel, and a total of 98 papers were considered in the final analysis. After 2 h, 28.6% of the patients of the placebo group improved and 8.8% were pain-free. The percentage of pain-free patients was the highest in the placebo and active drug groups in which the placebo or drug had been administered subcutaneously, in parallel design studies (vs. cross-over trials) and in studies performed in Europe (vs. North America). Adverse events in the placebo group were significantly higher in studies performed in North America. These data reinforce the need for knowing the magnitude of the placebo response in each specific situation during the planning of clinical trials on acute migraine.
Similar content being viewed by others
Notes
Reports two clinical studies.
Reports two clinical studies.
The paper reports results from more than one clinical trial.
The paper reports results from more than one clinical trial.
Reports two clinical studies.
References
Carli GF, Fabbri L, Cavazzuti L, Roncolato M, Agnello V, Recchia G (1998) The epidemiology of migraine: a retrospective study in Italian emergency departments. Headache 38:697–704
Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lanteri-Minet M, Lucas C, Pradalier A, Chazot G, El Hasnaoui A (2002) Prevalence and clinical characteristics of migraine in France. Neurology 23:232–237
Snow V, Weiss K, Wall EM, Mottur-Pilson C (2002) Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 137:840–849
Aukerman G, Knutson D, Miser WF (2002) Management of the acute migraine headache. Am Fam Physician 66:2123–2130
Gladstone JP, Dodick DW (2004) Revised 2004 International Classification of Headache Disorders: new headache types. Can J Neurol Sci 31:3004–3014
Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine – current understanding and treatment. N Engl J Med 346:257–270
Hughes EG (2003) Randomized clinical trials: the meeting place of medical practice and clinical research. Semin Reprod Med 21:55–64
Macedo A, Farré M, Baños JE (2003) Placebo effect and placebos: what are we talking about? Some conceptual and historical considerations. Eur J Clin Pharmacol 59:337–342
González de Dios J (2001) De la medicina basada en la evidencia a la evidencia basada en la medicina. Ann Esp Pediatr 55:429–439
Calvo CB, Rubinstein A (2002) Influence of new evidence on prescription patterns. J Am Board Fam Pract 15:457–462
Fairhurst K, Huby G (1998) From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. BMJ 317:1130–1134
Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence-b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173
Macedo A, Sampaio C (2001) Influence of placebo effect on planning and analysis of clinical trials. Rev Port Cardiol 20:313–319
Burdett S, Stewart LA, Tierney JF (2003) Publication bias and meta-analyses: a practical example. Int J Technol Assess Health Care 19:129–134
Ernst E, Resch KL (1995) Concept of true and perceived placebo effects. BMJ 311:551–553
Buckalew LW, Coffield KE (1982) An investigation of drug expectancy as a function of capsule color and size and preparation form. J Clin Psychopharmacol 2:245–248
de Craen AJ, Tijssen JG, de Gans J, Kleijnen J (2000) Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 247:183–188
Schwartz NA, Turturro MA, Istvan DJ, Larkin GL (2000) Patients’ perceptions of route of nonsteroidal anti-inflammatory drug administration and its effect on analgesia. Acad Emerg Med 7:857–861
Flaten, M A, Simonses T, Olsen H (1999) Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosom Med 61:250–255
Averbuch M, Katzper M (2001) Gender and the placebo analgesic effect in acute pain. Clin Pharmacol Ther 70:287–291
McQuay H, Carroll D, Moore A (1995) Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain 64:331–335
Jones SF, McQuay HJ, Moore RA, Hand CW (1998) Morphine and ibuprofen compared using the cold pressor test. Pain 34:117–122
Kilo S, Forster C, Geisslinger G, Brune K, Handwerker HO (1995) Inflammatory models of cutaneous hyperalgesia are sensitive to effects of ibuprofen in man. Pain 62:187–193
Petersen KL, Jones B, Segredo V, Dahl JB, Rowbotham MC (2001) Effect of remifentanil on pain and secondary hyperalgesia associated with the heat-capsaicin sensitization model in healthy volunteers. Anesthesiology 94:15–20
Steen KH, Reeh PW, Kreysel HW (1995) Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. Pain 62:339–347
Telekes A, Holland RL, Peck AW (1997) Indomethacin: effects on cold-induced pain and the nervous system in healthy volunteers. Pain 30:321–328
Voudouris NJ, Peck CL, Coleman G (1989) Conditioned response models of placebo phenomena: further support. Pain 38:109–116
Bigal ME, Bigal JO, Bordini CA, Speciali JG (2001) Evaluation of placebo use in migraine without aura, migraine with aura and episodic tension-type headache acute attacks. Arq Neuropsiquiatr 59:552–558
Chvetzoff G, Tannock IF (2003) Placebo effects in oncology. J Natl Cancer Inst 95:19–29
Pollo A, Vighetti S, Rainero I, Benedetti F (2003) Placebo analgesia and the heart. Pain 102:125–133
Hrobjartsson A, Gotzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594–1602
Hrobjartsson A, Gotzsche PC (2003) Placebo treatment versus no treatment. Cochrane Database Syst Rev 2003;1:CD003974
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (for the QUOROM Group) (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354:1896–1900
Headache Classification Committee of the IHS (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1–96
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
Diversity and heterogeneity – http://www.cochrane-net.org/openlearning/HTML/mod13-4.htm (consulted November 18, 2003)
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658
Oldman AD, Smith LA, McQuay HJ, Moore RA (2002) Pharmacological treatments for acute migraine: quantitative systematic review. Pain 97:247–257
Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, Zhu Q, Reiling J, Pace B (2002) Publication bias in editorial decision making. JAMA 287:2825–2828
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Articles included in the meta-analysis
(No authors listed) (1995) Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache 35:177–84
(No authors listed) (1999) Acute treatment of migraine attacks: efficacy and safety of a non-steroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 19:232–240
Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, Visser WH (1999) Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 19:525–530
Banerjee M, Findley LJ (1992) Sumatriptan in the treatment of acute migraine with aura. Cephalalgia 12:39–44
Bigal ME, Bordini CA, Tepper SJ, Speciali JG (2002) Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 42:862–871Footnote 1
Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G (1994) Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1,000 mg and placebo in acute migraine attack. Cephalalgia 14:156–161
Bousser MG, D’Allens H, Richard A (1993) Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. J Intern Med 234:211–216
Cabarrocas X; Almotriptan Study Group (2001) Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther 23:1867–1875
Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ (1993) Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 43:1363–1368
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831–2835
Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D (2004) Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 26:214–223
Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG (1994) Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 14:297–300
Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M (2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs17:653–667
Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB (2001) Efficacy of non-prescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 41:665–679
Couch JR, Saper J, Meloche JP. (1996) Treatment of migraine with BMS180048:response at 2 hours. Headache. 36:523–530
Cutler N, Mushet GR, Davis R, Clements B, Whitcher L (1995) Oral sumatriptan for the acute treatment of migraine: evaluation of three dosages strengths. Neurology 45[Suppl 7]:5–9
Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H, Olah TV, Reines SA. (1996). Pilot study of MK-462 in migraine. Cephalalgia. 16:113–116
Dahlof C, Bjorkman R. (1993) Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 13:117–123
Dahlof C, Edwards C, Toth A (1992) Sumatriptan injection is superior to placebo in the acute treatment of migraine-with regard to both efficacy and general well-being. Cephalalgia.12:214–220
Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A (2001) Dose finding, placebo-controlled study of oral almotriptan in acute treatment of migraine. Neurology 57:1811–1817
Dib M, Massiou H et al. (2002) Efficacy of oral ketoprofen in acute migraine. Neurology 58:1660–1665
Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P (1999) Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 19:699–700.
Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. (2002) Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 47:99–107
Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlof C, Mathew N; Study Group (2001) The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia.21:672–679
Diener HC (1999) Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 19:581–588
Dowson AJ, MacGregor EA et al. (2002) Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalagia 22:101–106
Dowson AJ, Massiou H, Laínez JM, Cabarrocas X (2002) Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 22:453–461
Dowson AJ, Massiou H, Lainez JM, Cabarrocas X (2004) Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 44:318–322
Ensink FB (1991) Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. J Neurol 238[Suppl 1]:S66–S69Footnote 2
Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J (2003) Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 23:869–876
Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC et al. (2000) Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 20:30–38
Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A et al. (1997) Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17:647–651
Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC et al. (2000) Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 54:156–163
Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF et al. (1991) Oral sumatriptan in acute migraine. Lancet 338:782–783
Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW et al. (2001) Selective serotonin 1F (5-HT1F) receptor agonist ly334370 for acute migraine: a randomized controlled trial. Lancet 358:1230–1234
Goldstein DJ, WNG O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17:785–790
Goldstein J, Dahlof CG, Diener HC, Olesen J, Schellens R, Senard JM, Simard D, Steiner TJ (1996) Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group. Cephalalgia 16:497–502
Goldstein J, Hoffman HD, Armellino JJ, Battika JP, Hamelsky SW, Couch J, Blumenthal H (1999) Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 19:684–691
Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA, Lines C (1998) Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 38:737–47
Gómez-Mancilla B, Cutler NR, Leibowitz MT, Spierings ELH, Klapper JA, Diamond S et al. (2001) Safety and efficacy of pnu-142633, a selective 5-ht1d agonist, in patients with acute migraine. Cephalalgia 21:727–32
Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H (1994) Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group. Headache 34:559–563
Hammalainen ML, Hoppu K, Santavuori P (1997) Sumatriptan for migraine attacks in children: a randomized placebo-controlled study: do children with migraine respond to oral sumatriptan differently from adults. Neurology 48:1100–1103
Hammalainen ML, Hoppu K, Valkeila E, Santavuori P (1997) Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 48:103–107
Havanka H, Dahlof C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H (2000) Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 22:970–980
Henry P, d’Allens H (1993) Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble. Headache 33:432–435
Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, Saper JR, Solomon S (1995) Transnasal butorphanol in the treatment of acute migraine. Headache 35:65–69
Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF et al. (2000) Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 20:233–243
Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. results of a double-blind, placebo-controlled, parallel-group study. Headache 37:640–645
Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP et al. (1998) A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 51:773–781
Krymchantowski AV, Barbosa JS, Cheim C, Alves LA (2001) Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study. Arq Neuropsiquiatr 59:46–49
Lange R, Scwarz JA, Hohn M (2000) Acetylsalicylic acid effervescent 1,000 mg (aspirin) in acute migraine attacks: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 20:663–667
Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S et al. (2002) Children’s ibuprofen suspension for the acute treatment of paediatric migraine. Headache 42:780–786
Lipton R, Baggish J, Stewart W, Codispoti J, Fu M (2000) Efficacy and safety of acetaminophen in the treatment of migraine. Arch Intern Med 160:3486–3492Footnote 3
Lipton RB, Stewart WF, Cady R, Hall C, O’Quinn S, Kuhn T, et al. (2000) Sumatriptan for the range of headaches in migraine sufferers:results of the spectrum study. Headache 40:783–791
Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F (1998) Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain. Arch Neurol 55:210–217
Mathew NT, Asgharnejad M, Peykamian M, Laurenza A (1997) Naratriptan Is Effective and well tolerated in the acute treatment of migraine:results of a double-blind, placebo-controlled, crossover-study. Neurology 49:1485–1490
Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR (2003) Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 43:214–222
Myllylä VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J et al. (1998) Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine:comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 38:201–207
Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O (1994) Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 241:138–144
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM; BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110
Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M et al. (2000) Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 20:588–596
Pascual J, Vega P, Diener H-C, Allen C, Vrijens F, Patel K (2000) Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 20:455–461
Patten JP, for the Oral Sumatriptan Dose-defining Study Group (1991) Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. Neurology 238:62–65.
Peikert A, Becker WJ, Ashford EA, Dahlof C, Hassani H, Salonen RJ (1999) Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. Eur J Neurol 6:43–49
Pfaffenrath V, Cunin G, Sjonell G, Prendergast S (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38:184–190
Pfaffenrath V, Oestreich W, Haase W (1990) Flunarizine (10 and 20 mg) i.v. versus placebo in the treatment of acute migraine attacks: a multi-centre double-blind study. Cephalalgia 10:77–81
Pini L, Sternieri E, Fabbri L, Zerbini O, Bamfi F (1995) High efficacy and low frequency of headache recurrence after oral sumatriptan. J Int Med Res 23:96–105
Rapoport A, Ryan R, Goldstein J, Keywood C (2002) Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 42[Suppl 2]:S74–S83
Rapport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL (1997) Optimizing the dose of zolmitriptan (zoming, 311 c90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 49:1210–1218
Rederich G, Rapport A, Cutler N, Hazelrigg R, Jamerson B (1995) Oral sumatriptan for the long-term treatment of migraine:clinical findings. Neurology 45[Suppl 7]:15–20
Roon K et al. (2000) No acute antimigraine efficacy of cp-12,.288, a highly potent inhibitor of neurogenic inflammation. Ann Neurol 47:238–41
Rowat BM, Merrill CF, Davis A, South V (1991) A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department. Cephalalgia 11:207–213
Russell MB, Holm-Thomsen OE, Rishoj Nielsen M, Cleal A, Pilgrim AJ, Olesen J (1994) A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 14:291–296
Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M (1997) Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 49:1225–1230
Ryan R, Géraud G, Goldstein J, Cady R, Keywood C (2002) Clinical efficacy of frovatriptan:placebo-controlled studies. Headache 42[Suppl 2]:S84–S92
Ryan RE Jr, Elkind A, Goldstein J (1997) Twenty-four-hour effectiveness of BMS 180048 in the acute treatment of migraine headaches. Headache 37:245–248
Sakai F, Diener HC, Ryan R, Poole P (2004) Eletriptan for the acute treatment of migraine:results of bridging a Japanese study to Western clinical trials. Curr Med Res Opin 20:269–277
Salonen R, Ashford E, Dahlof C, Dawson R, Gilhus NE, Luben V, Noronha D, Warter JM (1994) Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol 241:463–469Footnote 4,Footnote 5
Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S (2002) Electriptan vs sumatriptan. A double-blind, placebo-controlled, multiple migraine attack study. Neurology 59:1210–1207
Sargent J, Kierchner JR, Davis R, Kirkhart B (1995) Oral sumatriptan is effective and well tolerated for the acute treatment of migraine:results of a multicenter study. Neurology 45[SSuppl 7]:10–14
Sharma S, Prasad A, Nehru R, Anand KS, Rishi RK, Chaturvedi S et al. (2002) Efficacy and tolerability of prochlorperazine bucal tablets in treatment of acute migraine. Headache 42:896–902
Sheftell F, Ryan R, Pitman V; Eletriptan Steering Committee (2003) Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 43:202–213
Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P et al. (2004) Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 62:1552–1557
Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS (2003) Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial. Neurology 28/60:315–321
Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM (1997) Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 49:1219–1225
Stark R, Dahlöf C, Haughie S, Hettiarachchi (2002) Efficacy, safety and tolerability of oral eletriptan in acute treatment of migraine: results of a phase iii, multicentre, placebo-controlled study across three attacks. Cephalagia 22:23–32
Stark S, Spierings ELH, McNeal S, Putnam GP, Bolden-Watson CP, O’Quinn S. (2002) Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 40:513–520
Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR (2003) Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 23:942–952
Syrett N, Abu-Shakra S, Yates R (2003) Zolmitriptan nasal spray: advances in migraine treatment. Neurology 61[Suppl 4]:S27–S30
Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B et al. (1998) Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 38:281–287
Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W et al. (1998) Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 38:748–755
Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD (1996) 311C90, a new central and peripherally acting 5-HT1d receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 46:522–526
Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrrari MD (1996) Rizatriptan vs. Sumatriptan in the acute treatment of migraine. Arch Neurol 53:1132–1137
Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK (2002) Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 42:49–55
Rights and permissions
About this article
Cite this article
Macedo, A., Farré, M. & Baños, JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol 62, 161–172 (2006). https://doi.org/10.1007/s00228-005-0088-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0088-5